Lieming Ding

Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial

Yuankai Shi, Li Zhang, Xiaoqing Liu et al. · The Lancet Oncology · 2013 · 423 citations

Medicine, Oncology, Pharmacology +6

Icotinib versus chemotherapy as adjuvant treatment for stage II–IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial

Jianxing He, Chunxia Su, Wenhua Liang et al. · The Lancet Respiratory Medicine · 2021 · 184 citations

Medicine, Oncology, Pharmacology +13

Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial

Yunpeng Yang, Jianya Zhou, Jianying Zhou et al. · The Lancet Respiratory Medicine · 2019 · 136 citations

Medicine, Oncology, Pharmacology +16

Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies

Fenlai Tan, Xiaoyan Shen, Dechang Wang et al. · Lung Cancer · 2011 · 133 citations

Medicine, Oncology, Pharmacology +11

Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study

Shun Lü, Jianying Zhou, Hong Jian et al. · The Lancet Respiratory Medicine · 2023 · 71 citations

Medicine, Oncology, Pharmacology +14